Profil
Camille Landis worked as the Vice President of Business Development at Relypsa, Inc. from 2015 to 2017.
Prior to that, she was the Senior Vice President of Corporate Development at Unity Biotechnology, Inc. and the Chief Business Officer at Eidos Therapeutics, Inc. Ms. Landis received an undergraduate degree from the University of St. Thomas and an MBA from the Haas School of Business.
Ehemalige bekannte Positionen von Camille Landis
| Unternehmen | Position | Ende |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2018 |
| RELYPSA INC | Corporate Officer/Principal | 01.08.2017 |
| UNITY BIOTECHNOLOGY, INC. | Corporate Officer/Principal | - |
Ausbildung von Camille Landis
| University of St. Thomas | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
